{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T07:06:01Z","timestamp":1784185561105,"version":"3.55.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jiac.2026.103009","type":"journal-article","created":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T01:05:56Z","timestamp":1781312756000},"page":"103009","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Matching-adjusted comparison of the effectiveness and safety of Ensitrelvir versus Remdesivir for high-risk, hospitalized patients with non-severe COVID-19 in Japan"],"prefix":"10.1016","volume":"32","author":[{"given":"Yoshikazu","family":"Mutoh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4455-5540","authenticated-orcid":false,"given":"Toshiyuki","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koki","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0888-8564","authenticated-orcid":false,"given":"Yusuke","family":"Minato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Izumisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyoshi","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3160-5136","authenticated-orcid":false,"given":"Takumi","family":"Umemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumika","family":"Mizutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Soejima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Hagimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reoto","family":"Takei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Fukihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Sasano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Yamano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3944-6881","authenticated-orcid":false,"given":"Kensuke","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9745-3329","authenticated-orcid":false,"given":"Tomoki","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Ichihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Kondoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9620-2525","authenticated-orcid":false,"given":"Yohei","family":"Doi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Tsukada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2026.103009_bib2","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe Covid-19","volume":"382","author":"Grein","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2026.103009_bib3","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19 - Final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2026.103009_bib4","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa2116846","article-title":"Early remdesivir to prevent progression to severe Covid-19 in outpatients","volume":"386","author":"Gottlieb","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2026.103009_bib5","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1056\/NEJMoa2108163","article-title":"REGEN-COV antibody combination and outcomes in outpatients with Covid-19","volume":"385","author":"Weinreich","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2026.103009_bib6","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","article-title":"Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab","volume":"385","author":"Gupta","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2026.103009_bib7","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2026.103009_bib8","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2026.103009_bib9","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2026.103009_bib10","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients","volume":"386","author":"Jayk Bernal","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2026.103009_bib11","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00632-22","article-title":"Safety, tolerability, and pharmacokinetics of the novel antiviral agent ensitrelvir fumaric acid, a SARS-CoV-2 3CL protease inhibitor, in healthy adults","volume":"66","author":"Shimizu","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2026.103009_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/v15102052","article-title":"Pharmacokinetic and pharmacodynamic analysis of the 3CL protease inhibitor ensitrelvir in a SARS-CoV-2 infection mouse model","volume":"15","author":"Fukao","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.jiac.2026.103009_bib13","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.54991","article-title":"Efficacy and safety of 5-Day oral ensitrelvir for patients with mild to moderate COVID-19: the SCORPIO-SR randomized clinical trial","volume":"7","author":"Yotsuyanagi","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jiac.2026.103009_bib16","author":"The Japanese Association for Infectious Diseases"},{"key":"10.1016\/j.jiac.2026.103009_bib17","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1002\/med.21783","article-title":"What coronavirus 3C-like protease tells us: from structure, substrate selectivity, to inhibitor design","volume":"41","author":"Xiong","year":"2021","journal-title":"Med Res Rev"},{"key":"10.1016\/j.jiac.2026.103009_bib18","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1093\/jac\/dkad027","article-title":"Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo","volume":"78","author":"Kuroda","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2026.103009_bib19","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40261-023-01265-8","article-title":"Evaluation of the drug-drug interaction potential of ensitrelvir fumaric acid with cytochrome P450 3A substrates in healthy Japanese adults","volume":"43","author":"Shimizu","year":"2023","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.jiac.2026.103009_bib20","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s40121-024-00946-x","article-title":"Effect of renal impairment on pharmacokinetics and safety of Ensitrelvir, a SARS-CoV-2 3CL protease inhibitor","volume":"13","author":"Katsube","year":"2024","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jiac.2026.103009_bib21","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.42140","article-title":"Prevalence of contraindications to nirmatrelvir-ritonavir among hospitalized patients with COVID-19 at risk for progression to severe disease","volume":"5","author":"Hoertel","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jiac.2026.103009_bib22","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.jiac.2024.02.015","article-title":"Ensitrelvir in patients with SARS-CoV-2: a retrospective chart review","volume":"30","author":"Yamato","year":"2024","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2026.103009_bib23","article-title":"Real-world efficacy of ensitrelvir in hospitalized patients with COVID-19 in Japan: a retrospective observational study","volume":"16","author":"Yoshida","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.jiac.2026.103009_bib24","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1007\/s40121-024-01010-4","article-title":"Real-World effectiveness of ensitrelvir in reducing severe outcomes in outpatients at high risk for COVID-19","volume":"13","author":"Takazono","year":"2024","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jiac.2026.103009_bib25","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1056\/NEJMoa2309003","article-title":"Nirmatrelvir for vaccinated or unvaccinated adult outpatients with Covid-19","volume":"390","author":"Hammond","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2026.103009_bib26","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0140-6736(22)02597-1","article-title":"Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial","volume":"401","author":"Butler","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jiac.2026.103009_bib27","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/cid\/ciaf029","article-title":"Ensitrelvir for the treatment of nonhospitalized adults with COVID-19: results from the SCORPIO-HR, phase 3, randomized, double-blind, placebo-controlled trial","volume":"80","author":"Luetkemeyer","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2026.103009_bib28","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2024.29.1.2300703","article-title":"Early COVID-19 vaccine effectiveness of XBB.1.5 vaccine against hospitalisation and admission to intensive care, the Netherlands, 9 October to 5 December 2023","volume":"29","author":"van Werkhoven","year":"2024","journal-title":"Euro Surveill"},{"key":"10.1016\/j.jiac.2026.103009_bib29","doi-asserted-by":"crossref","first-page":"180","DOI":"10.15585\/mmwr.mm7308a5","volume":"73","author":"DeCuir","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jiac.2026.103009_bib30","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.10650","article-title":"Evaluation of waning of SARS-CoV-2 vaccine-induced immunity: a systematic review and meta-analysis","volume":"6","author":"Menegale","year":"2023","journal-title":"JAMA Netw Open"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X26001078?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X26001078?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T06:33:12Z","timestamp":1784183592000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X26001078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1341321X26001078"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2026.103009","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Matching-adjusted comparison of the effectiveness and safety of Ensitrelvir versus Remdesivir for high-risk, hospitalized patients with non-severe COVID-19 in Japan","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2026.103009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103009"}}